{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/corticosteroids-oral/","result":{"data":{"firstChapter":{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d72b9ffd-f9f1-4f94-973e-5dc5d78110a5 --><h1>Corticosteroids - oral: Summary</h1><!-- end field d72b9ffd-f9f1-4f94-973e-5dc5d78110a5 -->","htmlStringContent":"<!-- begin item 4b8cc538-0851-4774-a24f-72bcd0826803 --><!-- begin field da5b2b50-bf60-4e1f-90c7-0df55686b964 --><ul><li>Corticosteroids are synthetic analogues of hormones produced by the adrenal cortex.</li><li>Corticosteroids can have glucocorticoid or mineralocorticoid properties and different corticosteroids have varying ratios of these properties.<ul><li>Dexamethasone and prednisolone have high glucocorticoid activity.</li><li>Fludrocortisone acetate has high mineralocorticoid activity.</li></ul></li><li>As a general principle, short courses of oral corticosteroids (less than 3 weeks) can be stopped abruptly. Gradual withdrawal should be considered for people whose disease is unlikely to relapse and who have:<ul><li>Taken more than 40 mg oral prednisolone daily or equivalent for more than 1 week.</li><li>Taken repeated evening doses of corticosteroids.</li><li>Received more than 3 weeks of corticosteroid treatment.</li><li>Recently received repeated courses of corticosteroids (especially if taken for longer than 3 weeks), such as short courses repeatedly prescribed for the treatment of acute exacerbations of asthma.</li><li>A history of previous long-term therapy (months or years).</li><li>Other possible causes of adrenal suppression, such as excessive alcohol consumption or stress.</li></ul></li><li>If stress, for example caused by infection, trauma, or surgery, occurs up to 1 week after stopping the corticosteroid, additional corticosteroid cover should be prescribed to compensate for any potential adrenal suppression.</li><li>During withdrawal, the dose of oral corticosteroids may be reduced rapidly down to physiological doses (about 7.5 mg of prednisolone or equivalent) and reduced more slowly thereafter.</li><li>Oral corticosteroids:<ul><li>Are contraindicated in people with systemic infections, uncontrolled by appropriate antimicrobial therapy.</li><li>Should be used with caution in people with hepatic impairment; psychiatric disturbance including psychoses or severe affective disorders; wounds; other pre-existing conditions that can be exacerbated by oral corticosteroids, such as heart failure, diabetes mellitus, recent myocardial infarction, or hypertension. </li></ul></li><li>In pregnancy, the risks of oral corticosteroids should be weighed against the benefits.</li><li>The adverse effects of oral corticosteroids can be minimized by:<ul><li>Prescribing the lowest effective dose for the minimum time possible.</li><li>Morning dosing and (if the condition being treated will allow it) taking corticosteroids on alternate days. This may reduce the risk, or extent, of adrenal suppression.</li></ul></li><li>A steroid treatment card should be provided for people on long-term treatment.</li><li>Gastrointestinal protection with a proton pump inhibitor should not be provided routinely for people on long-term corticosteroids but should be considered for people at high risk of gastrointestinal bleeding or dyspepsia.</li><li>Advice should be offered:<ul><li>To those without a history of chickenpox or measles to avoid close contact with people who have chickenpox, shingles, or measles and to seek urgent medical advice if they are exposed.</li><li>To seek medical advice if any mood or behavioural changes are experienced.</li><li>That regular monitoring is required (for example, an eye examination every 6–12 months).</li></ul></li><li>Before initiating treatment with long-term oral corticosteroids, the following should be measured and regularly monitored:<ul><li>Blood pressure.</li><li>Body weight.</li><li>BMI.</li><li>Children’s height.</li><li>HbA1c, triglycerides, potassium levels.</li></ul></li><li>Ongoing monitoring should also include osteoporosis risk and falls risk assessment (if appropriate), measurement of height for children and adolescents, monitoring for signs of adrenal suppression, and regular eye examinations.</li></ul><!-- end field da5b2b50-bf60-4e1f-90c7-0df55686b964 --><!-- end item 4b8cc538-0851-4774-a24f-72bcd0826803 -->","topic":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e","topicId":"72c594bc-4c91-4d24-acdb-dda9812ea656","topicName":"Corticosteroids - oral","slug":"corticosteroids-oral","aliases":[],"chapters":[{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes"},{"id":"1684d913-6ee4-5c81-b8f5-da290e6b10d2","slug":"update","fullItemName":"Update"}]},{"id":"e478b1f3-4d1b-57d5-879f-ad9022a2ec8f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d57df389-307f-59f5-a5e5-f223861afaba","slug":"goals","fullItemName":"Goals"},{"id":"70adac45-ee10-56f9-b88b-e75007cba584","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe005751-eb99-5634-a99d-041d841fd184","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"854fdd1a-f9cd-5b0f-95b0-ce2693d04cc8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03f7459a-9d10-5435-af19-3cb0a39f0a88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c4a3b4a-3bfd-5b18-b16c-3350018754f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c243f116-7197-5797-8dea-f74bd970f4d7","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f776021e-e349-55a4-b655-4801dd7df8e5","slug":"definition","fullItemName":"Definition"},{"id":"241b5d44-7190-5d40-a453-c34255ed8c09","slug":"properties-of-corticosteroids","fullItemName":"Properties of corticosteroids"},{"id":"7cede1e7-70ca-59b2-a0b2-9da96d75e581","slug":"types-of-oral-corticosteroids","fullItemName":"Types of oral corticosteroids"},{"id":"00d48a00-08ac-5b67-a81d-79c587633318","slug":"equivalent-anti-inflammatory-doses","fullItemName":"Equivalent anti-inflammatory doses"}]},{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","slug":"management","fullItemName":"Management","subChapters":[{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids"}]},{"id":"6e288e6d-366d-5598-be63-4261ab6000a9","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"cd130a7b-8ddf-543d-a4d2-e2b78c7ebe73","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"3b37794e-a5f1-56b1-a7e0-230805f097a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3c6ec19-1d84-510b-b44b-43ccb32f6b86","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"60803b59-24a4-5036-b82f-40d837e8e318","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"28cc6229-02b0-596c-b492-3dd868d5230b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f63de84-1b36-5a2e-b3b3-626df702ff90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69d4244b-043f-55e0-80ac-64b46fe11694","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e","topicId":"72c594bc-4c91-4d24-acdb-dda9812ea656","topicName":"Corticosteroids - oral","slug":"corticosteroids-oral","aliases":[],"topicSummary":"Corticosteroids are synthetic analogues of hormones produced by the adrenal cortex.","lastRevised":"Last revised in June 2020","nextPlannedReviewBy":"2025-05-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-04","nextPlannedReviewByDisplay":"April 2025","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"}],"chapters":[{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes"},{"id":"1684d913-6ee4-5c81-b8f5-da290e6b10d2","slug":"update","fullItemName":"Update"}]},{"id":"e478b1f3-4d1b-57d5-879f-ad9022a2ec8f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d57df389-307f-59f5-a5e5-f223861afaba","slug":"goals","fullItemName":"Goals"},{"id":"70adac45-ee10-56f9-b88b-e75007cba584","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe005751-eb99-5634-a99d-041d841fd184","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"854fdd1a-f9cd-5b0f-95b0-ce2693d04cc8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03f7459a-9d10-5435-af19-3cb0a39f0a88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c4a3b4a-3bfd-5b18-b16c-3350018754f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c243f116-7197-5797-8dea-f74bd970f4d7","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f776021e-e349-55a4-b655-4801dd7df8e5","slug":"definition","fullItemName":"Definition"},{"id":"241b5d44-7190-5d40-a453-c34255ed8c09","slug":"properties-of-corticosteroids","fullItemName":"Properties of corticosteroids"},{"id":"7cede1e7-70ca-59b2-a0b2-9da96d75e581","slug":"types-of-oral-corticosteroids","fullItemName":"Types of oral corticosteroids"},{"id":"00d48a00-08ac-5b67-a81d-79c587633318","slug":"equivalent-anti-inflammatory-doses","fullItemName":"Equivalent anti-inflammatory doses"}]},{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","slug":"management","fullItemName":"Management","subChapters":[{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids"}]},{"id":"6e288e6d-366d-5598-be63-4261ab6000a9","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"cd130a7b-8ddf-543d-a4d2-e2b78c7ebe73","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"3b37794e-a5f1-56b1-a7e0-230805f097a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3c6ec19-1d84-510b-b44b-43ccb32f6b86","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"60803b59-24a4-5036-b82f-40d837e8e318","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"28cc6229-02b0-596c-b492-3dd868d5230b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f63de84-1b36-5a2e-b3b3-626df702ff90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69d4244b-043f-55e0-80ac-64b46fe11694","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e"}},"staticQueryHashes":["3666801979"]}